Jose Angel U. M.
- Country
- Spain
- Department
- Cardiology
Research Overview
- Phase IIb Randomized Double‑Blind Placebo‑Controlled Study of Eplontersen Plus ALXN2220 Versus Eplontersen + Placebo in Adults with Transthyretin‑Mediated Amyloid Cardiomyopathy
- Efficacy and Safety Evaluation of ALXN2220 in Adult Patients with Transthyretin Amyloid Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
- TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
Data & Insights
Has run more than one trial at 62 of 139 partner sites.
Specializations
Cardiovascular Specialization
The investigator specializes in treating patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a rare but serious cardiac condition affecting adults.
- Cardiac Amyloidosis Management
- Heart Failure Treatment
- Cardiovascular Clinical Events
Focus includes evaluating innovative therapeutic approaches for cardiac amyloidosis patients.
Rare Disease Expertise
Demonstrates particular interest in rare cardiac disorders, with specific emphasis on protein misfolding conditions affecting the heart.
- Protein-Related Cardiac Disorders
- Progressive Cardiac Conditions
- Adult Cardiac Care
Specializes in addressing complex manifestations of cardiac amyloidosis in adult populations.
Treatment Innovation
Engages in evaluation of new therapeutic approaches for cardiac amyloidosis treatment, focusing on targeted interventions for ATTR-CM.
- Novel Therapeutic Assessment
- Cardiovascular Outcomes
- Treatment Safety Evaluation
Investigates treatments aimed at improving cardiovascular outcomes in affected patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.